Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Quarterly results
Director departure
CC transcript
ALBIREO PHARMA, INC. (ALBO) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/29/2021 GN Albireo to Report First Quarter 2021 Financial Results on May 6
04/06/2021 GN Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
03/25/2021 GN Albireo Announces First Patients Dosed in Two New Studies
02/26/2021 GN Albireo Spotlights Global Patient Communities on Rare Disease Day
02/25/2021 GN Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
02/23/2021 GN Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
02/18/2021 GN Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
02/17/2021 GN Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/11/2021 GN Albireo Presents Odevixibat Commercialization Road to $1 Billion
01/25/2021 GN Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
01/22/2021 GN Albireo Recognizes International Alagille Syndrome Awareness Day 2021
01/07/2021 GN Albireo to Host Virtual Investor Commercial Day 2021
01/06/2021 GN Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/08/2020 GN Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
11/13/2020 GN New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
11/05/2020 GN Albireo Reports Q3 2020 Financial Results and Provides Business Update
10/23/2020 GN Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting
10/05/2020 GN Albireo Recognizes PFIC Awareness Day 2020
10/02/2020 GN Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/08/2020 GN Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock
09/08/2020 GN Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC
09/07/2020 GN Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020
08/18/2020 GN Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
06/10/2020 GN Albireo to Host Key Opinion Leader Call on Clinical Outcome Assessments
06/09/2020 GN Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022
05/26/2020 GN Albireo to Present at 2020 Jefferies Virtual Healthcare Conference
05/07/2020 GN Albireo Reports Q1 2020 Financial Results and Provides Business Update
04/07/2020 GN Albireo to Present at 19th Annual Needham Healthcare Conference
03/10/2020 GN Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
02/26/2020 GN Albireo to Present at Cowen and Company 40th Annual Health Care Conference
02/24/2020 GN Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March 2
01/29/2020 GN Albireo Prices $40 Million Public Offering of Common Stock
01/29/2020 GN Albireo Announces Proposed Public Offering of Common Stock
11/14/2019 GN Albireo to Present at the Jefferies 2019 London Healthcare Conference
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy